Last week in M&A was the best that 2023 has had to offer thus far. Wachtell, Lipton, Rosen & Katz and Sullivan & Cromwell led a $43 billion biotech deal, while Latham & Watkins, Shearman & Sterling and Freshfields, Bruckhaus & Derringer steered a $12.5 billion software deal.

That should be good news for the deal world, but some fresh dark clouds—first appearing in the form of an old-fashioned bank panic—could ultimately lead to rain on the parade.

This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.

To view this content, please continue to their sites.

Not a Lexis Subscriber?
Subscribe Now

Not a Bloomberg Law Subscriber?
Subscribe Now

Why am I seeing this?

LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.

For questions call 1-877-256-2472 or contact us at [email protected]